Skip to main content
SpringerLink
Log in
Book cover

Coagulation in Cancer pp 223–242Cite as

Thrombosis in Childhood Cancer

  • Chapter
  • First Online:

  • 1307 Accesses

Part of the book series: Cancer Treatment and Research ((CTAR,volume 148))

Over the past five decades, the survival rate for children diagnosed with oncologic disease has dramatically increased from less than 20% to almost 80%. Accordingly, an area of growing interest and concern is the long-term effects of the patients’ disease and therapy. Thromboembolic events (TEE) occur with greater frequency in children and adults with cancer and have been extensively studied in the latter population. However, given the relative infrequency of TEE in the general pediatric population and paucity of coordinated efforts, information on the incidence, nature and impact of thrombosis in children with cancer has been lacking until recently. In this chapter, we address the salient features of TEEs in the pediatric cancer patient.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117:19–25.

    PubMed  Google Scholar 

  2. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83:657–660.

    PubMed  CAS  Google Scholar 

  3. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83:1251–1257.

    PubMed  CAS  Google Scholar 

  4. Stein PD, Kayali F, Olson RE. Incidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey. J Pediatr. 2004;145:563–565.

    PubMed  Google Scholar 

  5. van Ommen CH, Heijboer H, Buller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr. 2001;139:676–681.

    PubMed  Google Scholar 

  6. Kuhle S, Lau A, Bajzar L, et al. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study. Br J Haematol. 2006;134:526–531.

    PubMed  CAS  Google Scholar 

  7. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res. 2003;111:125–131.

    PubMed  CAS  Google Scholar 

  8. Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108:2216–2222.

    PubMed  CAS  Google Scholar 

  9. Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer. 2003;97:508–516.

    PubMed  CAS  Google Scholar 

  10. Farinasso L, Bertorello N, Garbarini L, et al. Risk factors of central venous lines-related thrombosis in children with acute lymphoblastic leukemia during induction therapy: a prospective study. Leukemia. 2007;21:552–556.

    PubMed  CAS  Google Scholar 

  11. Deitcher SR, Gajjar A, Kun L, Heideman RL. Clinically evident venous thromboembolic events in children with brain tumors. J Pediatr. 2004;145:848–850.

    PubMed  Google Scholar 

  12. Tabori U, Beni-Adani L, Dvir R, et al. Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr Blood Cancer. 2004;43:633–636.

    PubMed  Google Scholar 

  13. Paz-Priel I, Long L, Helman LJ, Mackall CL, Wayne AS. Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol. 2007;25:1519–1524.

    PubMed  Google Scholar 

  14. Gitlin D, Biasucci A. Development of gamma G, gamma A, gamma M, beta IC-beta IA, C 1 esterase inhibitor, ceruloplasmin, transferrin, hemopexin, haptoglobin, fibrinogen, plasminogen, alpha 1-antitrypsin, orosomucoid, beta-lipoprotein, alpha 2-macroglobulin, and prealbumin in the human conceptus. J Clin Invest. 1969;48:1433–1446.

    PubMed  CAS  Google Scholar 

  15. Reverdiau-Moalic P, Delahousse B, Body G, Bardos P, Leroy J, Gruel Y. Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood. 1996;88:900–906.

    PubMed  CAS  Google Scholar 

  16. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood. 1988;72:1651–1657.

    PubMed  CAS  Google Scholar 

  17. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood. 1987;70:165–172.

    PubMed  CAS  Google Scholar 

  18. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood. 1992;80:1998–2005.

    PubMed  CAS  Google Scholar 

  19. Mautone A, Giordano P, Montagna O, Quercia M, Altomare M, De Mattia D. Coagulation and fibrinolytic systems in the ill preterm newborn. Acta Paediatr. 1997;86:1100–1104.

    PubMed  CAS  Google Scholar 

  20. Israels SJ, Rand ML, Michelson AD. Neonatal platelet function. Semin Thromb Hemost. 2003;29:363–372.

    PubMed  CAS  Google Scholar 

  21. Katz JA, Moake JL, McPherson PD, et al. Relationship between human development and disappearance of unusually large von Willebrand factor multimers from plasma. Blood. 1989;73:1851–1858.

    PubMed  CAS  Google Scholar 

  22. Michelson AD. Platelet function in the newborn. Semin Thromb Hemost. 1998;24:507–512.

    PubMed  CAS  Google Scholar 

  23. Weinstein MJ, Blanchard R, Moake JL, Vosburgh E, Moise K. Fetal and neonatal von Willebrand factor (vWF) is unusually large and similar to the vWF in patients with thrombotic thrombocytopenic purpura. Br J Haematol. 1989;72:68–72.

    PubMed  CAS  Google Scholar 

  24. Israels SJ, McMillan-Ward E. Neonatal platelet procoagulant activity. Blood. 2002;100.

    Google Scholar 

  25. Michelson AD, Rajasekhar D, Bednarek FJ, Barnard MR. Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: differences between neonates and adults. Thromb Haemost. 2000;84:689–694.

    PubMed  CAS  Google Scholar 

  26. Schwarz HP, Muntean W, Watzke H, Richter B, Griffin JH. Low total protein S antigen but high protein S activity due to decreased C4b-binding protein in neonates. Blood. 1988;71:562–565.

    PubMed  CAS  Google Scholar 

  27. Monagle P, Chan AK, Albisetti M, Vegh P, Andrew M, Mitchell L. Fibrinolytic system in adolescents: response to venous occlusion stress tests. Pediatr Res. 2003;53:333–337.

    PubMed  CAS  Google Scholar 

  28. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost. 2004;2:402–413.

    PubMed  CAS  Google Scholar 

  29. Butenas S, van't Veer C, Mann KG. “Normal” thrombin generation. Blood. 1999;94:2169–2178.

    PubMed  CAS  Google Scholar 

  30. Andrew M, Schmidt B, Mitchell L, Paes B, Ofosu F. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin. Thromb Haemost. 1990;63:27–30.

    PubMed  CAS  Google Scholar 

  31. Cvirn G, Gallistl S, Muntean W. Effects of alpha(2)-macroglobulin and antithrombin on thrombin generation and inhibition in cord and adult plasma. Thromb Res. 2001;101:183–191.

    PubMed  CAS  Google Scholar 

  32. Schmidt B, Mitchell L, Ofosu FA, Andrew M. Alpha-2-macroglobulin is an important progressive inhibitor of thrombin in neonatal and infant plasma. Thromb Haemost. 1989;62:1074–1077.

    PubMed  CAS  Google Scholar 

  33. Gordon SG, Cross BA. A factor X-activating cysteine protease from malignant tissue. J Clin Invest. 1981;67:1665–1671.

    PubMed  CAS  Google Scholar 

  34. Olas B, Wachowicz B, Mielicki WP. Cancer procoagulant and blood platelet activation. Cancer Lett. 2001;169:165–171.

    PubMed  CAS  Google Scholar 

  35. Pineo GF, Regoeczi E, Hatton MW, Brain MC. The activation of coagulation by extracts of mucus: a possible pathway of intravascular coagulation accompanying adenocarcinomas. J Lab Clin Med. 1973;82:255–266.

    PubMed  CAS  Google Scholar 

  36. VanDeWater L, Tracy PB, Aronson D, Mann KG, Dvorak HF. Tumor cell generation of thrombin via functional prothrombinase assembly. Cancer Res. 1985;45:5521–5525.

    PubMed  CAS  Google Scholar 

  37. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266.

    PubMed  CAS  Google Scholar 

  38. Kwaan HC. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev. 1992;11:291–311.

    PubMed  CAS  Google Scholar 

  39. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 1993;73:161–195.

    PubMed  CAS  Google Scholar 

  40. Giordano P, Del Vecchio GC, Santoro N, et al. Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups. Pediatr Hematol Oncol. 2000;17:667–672.

    PubMed  CAS  Google Scholar 

  41. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L-asparaginase-induced antithrombin III deficiency. Blood. 1994;83:386–391.

    PubMed  CAS  Google Scholar 

  42. Oner AF, Gurgey A, Kirazli S, Okur H, Tunc B. Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase. Leuk Lymphoma. 1999;33:361–364.

    PubMed  CAS  Google Scholar 

  43. Rodeghiero F, Castaman G, Dini E. Fibrinopeptide A changes during remission induction treatment with L-asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation. Thromb Res. 1990;57:31–38.

    PubMed  CAS  Google Scholar 

  44. Mitchell LG, Halton JM, Vegh PA, et al. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. Am J Pediatr Hematol Oncol. 1994;16:120–126.

    PubMed  CAS  Google Scholar 

  45. Abshire TC, Gold SH, Odom LF, Carson SD, Hathaway WE. The coagulopathy of childhood leukemia. Thrombin activation or primary fibrinolysis? Cancer. 1990;66:716–721.

    PubMed  CAS  Google Scholar 

  46. Semeraro N, Montemurro P, Giordano P, Santoro N, De Mattia D, Colucci M. Increased mononuclear cell tissue factor and type-2 plasminogen activator inhibitor and reduced plasma fibrinolytic capacity in children with lymphoma. Thromb Haemost. 1994;72:54–57.

    PubMed  CAS  Google Scholar 

  47. Knofler R, Siegert E, Lauterbach I, et al. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy – impact of central venous lines. Eur J Pediatr. 1999;158 Suppl 3:S147–150.

    PubMed  Google Scholar 

  48. Mauz-Korholz C, Junker R, Gobel U, Nowak-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost. 2000;83:840–843.

    PubMed  CAS  Google Scholar 

  49. Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost. 2003;90:235–244.

    PubMed  CAS  Google Scholar 

  50. Nowak-Gottl U, Wermes C, Junker R, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood. 1999;93:1595–1599.

    PubMed  CAS  Google Scholar 

  51. Wermes C, von Depka Prondzinski M, Lichtinghagen R, Barthels M, Welte K, Sykora KW. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr. 1999;158 Suppl 3:S143–146.

    PubMed  Google Scholar 

  52. Gregory MA, Hadley GP. The evolution of biofilms in venous access devices implanted in children with Wilms' tumour. Pediatr Surg Int. 1998;13:400–405.

    PubMed  CAS  Google Scholar 

  53. Passerini L, Lam K, Costerton JW, King EG. Biofilms on indwelling vascular catheters. Crit Care Med. 1992;20:665–673.

    PubMed  CAS  Google Scholar 

  54. Krafte-Jacobs B, Sivit CJ, Mejia R, Pollack MM. Catheter-related thrombosis in critically ill children: comparison of catheters with and without heparin bonding. J Pediatr. 1995;126:50–54.

    PubMed  CAS  Google Scholar 

  55. Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Med. 2000;26:967–972.

    PubMed  CAS  Google Scholar 

  56. Du YJ, Brash JL, McClung G, Berry LR, Klement P, Chan AK. Protein adsorption on polyurethane catheters modified with a novel antithrombin-heparin covalent complex. J Biomed Mater Res A. 2007;80:216–225.

    PubMed  Google Scholar 

  57. Journeycake JM, Buchanan GR. Catheter-related deep venous thrombosis and other catheter complications in children with cancer. J Clin Oncol. 2006;24:4575–4580.

    PubMed  Google Scholar 

  58. Fratino G, Molinari AC, Parodi S, et al. Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. Ann Oncol. 2005;16:648–654.

    PubMed  CAS  Google Scholar 

  59. Male C, Chait P, Andrew M, Hanna K, Julian J, Mitchell L. Central venous line-related thrombosis in children: association with central venous line location and insertion technique. Blood. 2003;101:4273–4278.

    PubMed  CAS  Google Scholar 

  60. McLean TW, Fisher CJ, Snively BM, Chauvenet AR. Central venous lines in children with lesser risk acute lymphoblastic leukemia: optimal type and timing of placement. J Clin Oncol. 2005;23:3024–3029.

    PubMed  Google Scholar 

  61. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr. 1998;133:770–776.

    PubMed  CAS  Google Scholar 

  62. Kuhle S, Koloshuk B, Marzinotto V, et al. A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb Res. 2003;111:227–233.

    PubMed  CAS  Google Scholar 

  63. Ruud E, Holmstrom H, Hopp E, Wesenberg F. Central line-associated venous late effects in children without prior history of thrombosis. Acta Paediatr. 2006;95:1060–1065.

    PubMed  Google Scholar 

  64. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res. 2003;111:199–212.

    PubMed  CAS  Google Scholar 

  65. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006;118:555–568.

    PubMed  CAS  Google Scholar 

  66. Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost. 1999;25:137–145.

    PubMed  CAS  Google Scholar 

  67. Priest JR, Ramsay NK, Bennett AJ, Krivit W, Edson JR. The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr. 1982;100:990–995.

    PubMed  CAS  Google Scholar 

  68. Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res. 2000;99:503–509.

    PubMed  CAS  Google Scholar 

  69. Broome JD. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J Exp Med. 1963;118:99–120.

    PubMed  CAS  Google Scholar 

  70. Conard J, Durand G, Feger J, Samama M. Acquired abnormal antithrombin III in L-asparaginase treated patients? IVth International Congress on Thrombosis and Haemostasis. Vienna; 1973:193.

    Google Scholar 

  71. Land VJ, Sutow WW, Fernbach DJ, Lane DM, Williams TE. Toxicity of L-asparginase in children with advanced leukemia. Cancer. 1972;30:339–347.

    PubMed  CAS  Google Scholar 

  72. Priest JR, Ramsay NK, Latchaw RE, et al. Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer. 1980;46:1548–1554.

    PubMed  CAS  Google Scholar 

  73. Priest JR, Ramsay NK, Steinherz PG, et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr. 1982;100:984–989.

    PubMed  CAS  Google Scholar 

  74. Homans AC, Rybak ME, Baglini RL, Tiarks C, Steiner ME, Forman EN. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol. 1987;5:811–817.

    PubMed  CAS  Google Scholar 

  75. Pui CH, Jackson CW, Chesney C, et al. Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisone, and vincristine. J Clin Oncol. 1983;1:380–385.

    PubMed  CAS  Google Scholar 

  76. Ruud E, Holmstrom H, de Lange C, Natvig S, Albertsen BK, Wesenberg F. Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study. Pediatr Hematol Oncol. 2006;23:207–216.

    PubMed  CAS  Google Scholar 

  77. Bushman JE, Palmieri D, Whinna HC, Church FC. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res. 2000;24:559–565.

    PubMed  CAS  Google Scholar 

  78. Jaime-Perez JC, Gomez-Almaguer D. Platelet aggregation is stimulated by L-asparginase in children with acute lymphoblastic leukemia and normal individuals. Haematologica. 2002;87:891–892.

    PubMed  Google Scholar 

  79. Isacson S. Effect of prednisolone on the coagulation and fibrinolytic systems. Scand J Haematol. 1970;7:212–216.

    PubMed  CAS  Google Scholar 

  80. Ozsoylu S, Strauss HS, Diamond LK. Effects of corticosteroids on coagulation of the blood. Nature. 1962;195:1214–1215.

    PubMed  CAS  Google Scholar 

  81. Ozturk G, Ozsoylu S, Gursel T. Effects of methylprednisolone on FVIII:C and vWF levels. Eur J Haematol. 1994;53:119–120.

    PubMed  CAS  Google Scholar 

  82. Patrassi GM, Dal Bo Zanon R, Boscaro M, Martinelli S, Girolami A. Further studies on the hypercoagulable state of patients with Cushing's syndrome. Thromb Haemost. 1985;54:518–520.

    PubMed  CAS  Google Scholar 

  83. Patrassi GM, Sartori MT, Livi U, et al. Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation. Transplantation. 1997;64:1610–1614.

    PubMed  CAS  Google Scholar 

  84. Patrassi GM, Sartori MT, Rigotti P, et al. Reduced fibrinolytic potential one year after kidney transplantation. Relationship to long-term steroid treatment. Transplantation. 1995;59:1416–1420.

    PubMed  CAS  Google Scholar 

  85. Patrassi GM, Sartori MT, Viero ML, Scarano L, Boscaro M, Girolami A. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagul Fibrinolysis. 1992;3:789–793.

    PubMed  CAS  Google Scholar 

  86. Sartori MT, Patrassi GM, Rigotti P, et al. Improved fibrinolytic capacity after withdrawal of steroid immunosuppression in renal transplant recipients. Transplantation. 2000;69:2116–2121.

    PubMed  CAS  Google Scholar 

  87. Sartori MT, Rigotti P, Marchini F, et al. Plasma fibrinolytic capacity in renal transplant recipients: effect of steroid-free immunosuppression therapy. Transplantation. 2003;75:994–998.

    PubMed  CAS  Google Scholar 

  88. Sartori TM, Maurizio PG, Sara P, et al. Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation. J Heart Lung Transplant. 1999;18:693–700.

    PubMed  CAS  Google Scholar 

  89. van Giezen JJ, Jansen JW. Inhibition of fibrinolytic activity in-vivo by dexamethasone is counterbalanced by an inhibition of platelet aggregation. Thromb Haemost. 1992;68:69–73.

    PubMed  Google Scholar 

  90. Nowak-Gottl U, Heinecke A, von Kries R, Nurnberger W, Munchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res. 2001;103:165–172.

    PubMed  CAS  Google Scholar 

  91. Nowak-Gottl U, Ahlke E, Fleischhack G, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood. 2003;101:2529–2533.

    PubMed  CAS  Google Scholar 

  92. Mewhort-Buist TA, Liaw PC, Patel S, Atkinson HM, Berry LR, Chan AK. Treatment of endothelium with the chemotherapy agent vincristine affects activated protein C generation to a greater degree in newborn plasma than in adult plasma. Thromb Res. 2008;122:418–426.

    PubMed  CAS  Google Scholar 

  93. Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children: American college of chest physicians evidencebased clinical practice guidelines (8th Edition). Chest. 2008;133:887S–968S.

    PubMed  CAS  Google Scholar 

  94. Ruud E, Holmstrom H, De Lange C, Hogstad EM, Wesenberg F. Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies--a randomized, controlled study. Acta Paediatr. 2006;95:1053–1059.

    PubMed  Google Scholar 

  95. Meister B, Kropshofer G, Klein-Franke A, Strasak AM, Hager J, Streif W. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50:298–303.

    PubMed  Google Scholar 

  96. Massicotte P, Julian JA, Gent M, et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res. 2003;109:85–92.

    PubMed  CAS  Google Scholar 

  97. Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res. 1994;35:78–83.

    PubMed  CAS  Google Scholar 

  98. McDonald MM, Jacobson LJ, Hay WW Jr, Hathaway WE. Heparin clearance in the newborn. Pediatr Res. 1981;15:1015–1018.

    PubMed  CAS  Google Scholar 

  99. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr. 1996;128:313–318.

    PubMed  CAS  Google Scholar 

  100. Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood. 1999;94:3007–3014.

    PubMed  CAS  Google Scholar 

  101. Andrew M, Brooker L, Leaker M, Paes B, Weitz J. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration. Thromb Haemost. 1992;68:325–330.

    PubMed  CAS  Google Scholar 

  102. Albisetti M. Thrombolytic therapy in children. Thromb Res. 2006;118:95–105.

    PubMed  CAS  Google Scholar 

  103. Leaker M, Massicotte MP, Brooker LA, Andrew M. Thrombolytic therapy in pediatric patients: a comprehensive review of the literature. Thromb Haemost. 1996;76:132–134.

    PubMed  CAS  Google Scholar 

  104. Zenz W, Arlt F, Sodia S, Berghold A. Intracerebral hemorrhage during fibrinolytic therapy in children: a review of the literature of the last thirty years. Semin Thromb Hemost. 1997;23:321–332.

    PubMed  CAS  Google Scholar 

  105. Goldenberg NA, Durham JD, Knapp-Clevenger R, Manco-Johnson MJ. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. Blood. 2007;110:45–53.

    PubMed  CAS  Google Scholar 

  106. Zenz W, Muntean W, Beitzke A, Zobel G, Riccabona M, Gamillscheg A. Tissue plasminogen activator (alteplase) treatment for femoral artery thrombosis after cardiac catheterisation in infants and children. Br Heart J. 1993;70:382–385.

    PubMed  CAS  Google Scholar 

  107. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001;102:V215–224.

    PubMed  CAS  Google Scholar 

  108. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res. 2000;47:763–766.

    PubMed  CAS  Google Scholar 

  109. Andrew M. Developmental hemostasis: relevance to hemostatic problems during childhood. Semin Thromb Hemost. 1995;21:341–356.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Feinberg School of Medicine, Children’s Memorial Hospital, Northwestern University, Chicago, IL, USA

    Geoffrey A. Allen

  2. Division of Hematology/Oncology, Children’s Memorial Hospital, 2300 Children’s Plaza, Box 30, Chicago, IIllinois 60614

    Rukhmi Bhat

Authors
  1. Geoffrey A. Allen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rukhmi Bhat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Geoffrey A. Allen .

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2009 Springer Science+Business Media, LLC

    About this chapter

    Cite this chapter

    Allen, G.A., Bhat, R. (2009). Thrombosis in Childhood Cancer. In: Kwaan, H., Green, D. (eds) Coagulation in Cancer. Cancer Treatment and Research, vol 148. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-79962-9_13

    Download citation

    • DOI: https://doi.org/10.1007/978-0-387-79962-9_13

    • Published:

    • Publisher Name: Springer, Boston, MA

    • Print ISBN: 978-0-387-79961-2

    • Online ISBN: 978-0-387-79962-9

    • eBook Packages: MedicineMedicine (R0)

    Publish with us

    Policies and ethics

    Search

    Navigation